Latest Regulatory Milestones News

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

Vysarn Limited reported a robust 31.5% increase in revenue to $140 million for FY2026, driven by strong performances across its industrial, advisory, and technology segments. The company is accelerating its national footprint with strategic acquisitions and progressing the Kariyarra Water Scheme.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.

EMVision Medical Devices has made significant strides in its emu™ bedside scanner pivotal trial and First Responder program, boosting FY26 revenue by 57% while trimming its net loss by 15%.

Jade Gas Holdings has lodged its initial Plan for Development of Operations and secured approval for a substantial 502 km² production licence area, marking pivotal steps towards commercialising Mongolia’s first coal bed methane project.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

BHP Group Limited posted robust FY2026 results with a 15% revenue increase, record copper production contributing over half of underlying EBITDA, and a total fully franked dividend of 172 US cents per share. The company advances growth projects, including the Jansen potash mine, while managing legacy Samarco liabilities and pursuing climate targets.

Bathurst Resources is set to submit a Fast Track Approvals Act application for its Buller Plateaux Continuation Project, aiming to unlock 20 million tonnes of coking coal over 25 years on New Zealand’s West Coast.